In Parkinson's disease (PD), gastrointestinal features are common and often precede the motor signs. Braak and colleagues proposed that PD may start in the gut, triggered by a pathogen, and spread to the brain. Numerous studies have examined the gut microbiome in PD, all found it to be altered, but found inconsistent results on associated microorganisms. Studies to date have been small (N=20 to 306) and are difficult to compare or combine due to varied methodology. We conducted a microbiome-wide association study (MWAS) with two large datasets for internal replication (N=333 and 507). We used uniform methodology when possible, interrogated confounders, and applied two statistical tests for concordance, followed by correlation network analysis to infer interactions. Fifteen genera were associated with PD at a microbiome-wide significance level, in both datasets, with both methods, with or without covariate adjustment. The associations were not independent, rather represented 3 clusters of co-occurring microorganisms. Cluster 1 was composed of opportunistic pathogens; all were elevated in PD. Cluster 2 were short-chain-fatty-acid producing bacteria; all were reduced in PD.
Introduction
PD is a common, progressive and debilitating disease which currently cannot be prevented or cured. With the exception of rare genetic forms, the cause of PD is unknown. Many susceptibility loci 1 and environmental risk factors 2 have been identified, but each has a modest effect on risk, and none is sufficient to cause disease. Gene-environment interaction studies have not been able to identify a causative combination. [3] [4] [5] [6] The triggers that cause PD are unknown.
The emerging information about the importance of the gut microbiome in human health and disease, 7 together with the well-established connection between PD and the gut including common and early occurrence of constipation, 8 inflammation, 9 and increased gut membrane permeability, 10 have raised the possibility that microorganisms in the gut may play a role in PD pathogenesis and prompted a fast growing literature on studies conducted in humans and wide (Figure 3, Supplementary Figure 1 ). The PD-associated genera mapped to three polymicrobial clusters. Porphyromonas, Prevotella, and Corynebacterium_1, which were elevated in PD, mapped to a community of highly correlated organisms, which we denoted as cluster 1. Cluster 1 was the most distinct cluster in the microbiome with correlations reaching r=0.82 (P<3E-4), the highest in the microbiome in our data. The 10 genera that were depleted in PD formed cluster 2, where eight of them clustered at r≥0.4 (P<3E-4), and remaining two (Oscillospira and Lachnospiraceae_UCG-004), clustered with the others at r=0.25 (P<3E-4) and r=0. 35 (P<3E-4) . Lactobacillus and Bifidobacterium, both elevated in PD, were correlated with each other at r=0.33 (P<3E-4), which we denoted as cluster 3. Correlations within each cluster were all in the positive direction; i.e., members of clusters 1 tended to increase in abundance together, cluster 2 decreased together, and cluster 3 increased together.
Functional characteristics
Analyses so far were all hypothesis-free, data-driven, and blind to the functional relevance of the microorganisms. Having identified the associations and their corresponding clusters, we broke the blind by searching PubMed. PubMed results on functional characteristics converged on clusters defined by agnostic network analysis. [44] [45] [46] Many, but not all species of Porphyromonas, Prevotella, and Corynebacterium are pathogens.
Corynebacterium diphtheriae is the leading cause of diphtheria. Porphyromonas gingivalis causes periodontal disease. We did not detect C. diphtheriae, and P. gingivalis was extremely rare in our samples. We were interested in knowing the species that made-up these three genera in our PD samples. The bioinformatic pipeline used in our study (DADA2 with SILVA as reference database) assigned the detected sequences (amplicon sequence variants, ASVs) to species if the sequences were 100% identical, otherwise, the ASV was unassigned to species. Genera in cluster 2: Of the ten PD-associated genera in cluster 2, three (Oscillospira, Lachnospiraceae_UCG-004 and Lachnospiraceae_ND3007_group) have been detected only by sequencing and not yet been cultured. The rest (Agathobacter, Blautia, Butyricicoccus, Faecalibacterium, Fusicatenibacter, Lachnospira and Roseburia) are all anaerobic, gram positive bacteria in the Ruminococcaceae, and Lachnospiraceae families. They are best known for producing short chain fatty acids (SCFA), mainly butyrate, which help maintain integrity of the gut membrane, and have anti-inflammatory properties. 47, 48 Genera in cluster 3: Lactobacillus 49 and Bifidobacteria 50 are anaerobic gram positive bacteria.
They are among ubiquitous inhabitants of the human gastrointestinal microbiome. They metabolize carbohydrates in plants and dairy, and are considered probiotic for their health benefits, 51, 52 although they have also been implicated as cause of infection and excessive immune stimulation in susceptible individuals. 52, 53 
Cause of disease or consequence of medication
Human association studies are powerful tools for identifying disease-relevant leads and to generate hypotheses that can then be tested experimentally. Even if we find a strong candidate that blurs the line between association and causality, we cannot prove that it preceded PD because there are decades of preclinical and prodromal disease, and we do not know when it all begins. While cause cannot be proven in these studies, we can sometimes tease out consequence.
Medications have profound effects on the microbiome. 33 Levodopa is the most commonly used PD medication (>85% of PD patients were on varying doses of levodopa). To gauge if the association of PD with any of the 15 genera was a consequence of levodopa treatment, we tested if the change in the differential abundance of the 15 genera correlated with increasing levodopa dose.
We found no significant evidence to suggest that the increasing abundance of Porphyromonas, Prevotella, or Corynebacterium_1 (cluster 1) correlated with levodopa therapy. We did find significant evidence in dataset 2 to suggest that increasing doses of levodopa were correlated with decreasing levels of SCFA producing organisms (Faecalibacterium P=0.01, Agathobacter P=0.02, Blautia P=5E-4, Roseburia P=0.02, Fusicatenibacter P=0.01, Lachnospira P=5E-3, Lachnospiraceae_ND3007_group P=5E-3, Lachnospiraceae_UCG-004 P=0.03). A similar pattern was present in dataset 1, albeit most did not reach statistical significance possibly due to the smaller sample size of dataset 1. We also detected significant correlation between increasing levodopa dose and increasing levels of Bifidobacterium (dataset 1 P=5E-3, dataset 2 P=2E-6) and Lactobacillus (dataset 2 P=4E-3). These data suggest that the increase in abundance of cluster 1 (opportunistic pathogens) is independent of levodopa, but that the reduction in cluster 2 (SCFA) and increase in cluster 3 (probiotics), if not solely a consequence of medication, worsen with increasing doses of levodopa.
Discussion
Summary We confirmed that the gut microbiome is altered in PD and showed that the PD effect on the global composition of the gut microbiome is independent of the effects of sex, age, BMI, constipation, gastrointestinal discomfort, geography, and diet. Using hypothesis-free microbiome-wide association studies we identified 15 PD-associated genera that achieved microbiome-wide significance in both datasets, with two methods, and with or without covariate adjustment. The 15 association signals were robust to the dramatic population-specific differences in the composition of microbiomes of the two datasets. We used hypothesis-free correlation network analysis to infer interactions and to identify communities of co-occurring microorganisms. Using this agnostic approach, we learned that the 15 PD-associated genera represent three polymicrobial clusters. Review of the literature revealed that the clusters, as defined by agnostic network analysis, also share functional characteristics. Our results suggest the gut microbiomes of persons with PD can present with (1) an overabundance of a polymicrobial cluster of opportunistic pathogens, (2) reduced levels of SCFA producing bacteria, and/or (3) elevated levels of carbohydrate metabolizers commonly known as probiotics.
Alignment with PD literature Reduced levels of SCFA producing bacteria 12, 14, 16, 18, 19, 21, 26, 27 and elevated levels of probiotic bacteria in PD 14, 16, 18, 21, [25] [26] [27] have been reported before, and thus are confirmatory. Overabundance of opportunistic pathogens was a novel finding. We suspect the reason we were able to detect these microorganisms is because they are rare ( Figure 2 ) and we had a much larger sample size and power than prior studies. The microorganisms identified in prior PD studies were among the more abundant microorganisms in the gut. There have been two systematic reviews of PD-microbiome studies, which clearly show the vast disparity in the findings, but also reveal few findings that have emerged in more than one study. 31, 32 The most recent review highlighted 6 associations that were significant in more than one study:
Faecalibacterium, Roseburia, Bifidobacterium, Lactobacillus, Akkemansia and Prevotella. 32 We confirmed the reduction in Faecalibacterium and Roseburia (cluster 2), and the increase in Bifidobacterium and Lactobacillus (cluster 3). We also confirmed increased Akkermansia in both datasets but it was only significant in dataset 1. Prevotella results are interesting, with Scheperjans et al. 11 and Petrov et al. 18 reporting it decreased in PD while we find it elevated in both datasets. The apparent inconsistency may be simply because what is being referred to as "Prevotella" is not the same in these studies. We all used different taxonomic classification:
Scheperjans et al. reported at the family level (Prevotellaceae), we at genus level (Prevotella), and Petrov et al. at species level (Prevotella copri). The SILVA database we used here, classified family Prevotellaceae into 11 genera. The more common genera in the Prevotellaceae family (Paraprevotella, Prevotella_9 and Prevotella_7) did in fact have lower frequencies in PD than in controls, as Scheperjans et al. observed, but the difference was not significant in our datasets (FDR>0.6 in both datasets). Species P. copri, which Petrov et al. found reduced in PD, was the main species of the Prevotella_9 genus, which was reduced in our PD samples as well but not significantly (FDR>0.8 in both datasets). We found instead elevated levels of the less common genus Prevotella (FDR=0.006 in dataset 1 and FDR=0.02 in dataset 2). These findings suggest family Prevotellaceae may be heterogenous in its association with PD. When comparing studies, another important consideration is the reference database: there are many and they have varied phylogenetic resolution and nomenclature. For example, genus Corynebacterium in NCBI is divided into 2 non-monophyletic genera in SILVA:
Corynebacterium_1 and Corynebacterium. Similarly, what is called genus Prevotella in NCBI, is divided into multiple non-monophyletic genera in SILVA (we detected Prevotella, Prevotella_2, Prevotella_6, Prevotella_7, and Prevotella_9). The varying resolution at which the tests are conducted, and the reference databases used, cause confusion in the literature.
Opportunistic pathogens
Overabundance of opportunistic pathogens in PD gut microbiome was a novel and potentially the most exciting finding of this study. Braak and colleagues originally hypothesized that non-inherited forms of PD are caused by a pathogen that can pass through the mucosal barrier of the gastrointestinal tract and spread to the brain through the enteric nervous system. 54, 55 While many aspects of Braak's hypothesis have gained support in recent years, there is no direct evidence that a pathogen is involved. Presence of a-synuclein in the gastrointestinal tract has been documented in persons with established Lewy body disease 56 as well as those with rapid eye movement sleep behavior disorder which is considered prodromal PD. 57 Epidemiological studies suggest that truncal vagotomy if conducted decades before onset of PD reduces risk of developing PD. 58, 59 In a mouse model, a-synuclein fibrils injected into the gut induced a-synuclein pathology which spread to the brain resulting in Parkinsonian neurodegeneration and behavioral phenotype; whereas truncal vagotomy and asynuclein deficiency prevented the gut-to-brain spread and the associated neurodegeneration. 60 Human studies unrelated to PD have shown that infection in the gut or the olfactory system induce a-synuclein expression, and the increased abundance of a-synuclein mobilizes the immune system to fight the pathogen. 61, 62 It was also shown in a genetic model of PD (pink1 knock-out mice) that intestinal infection by pathogens elicits activation of cytotoxic T cells in the periphery and the brain and leads to deterioration of dopaminergic cells and motor impairment, suggesting that intestinal infection acts as a triggering event in PD. 63 Despite the increasing evidence linking the gut, a-synuclein, and inflammation to PD, there is no direct evidence that a pathogen is responsible for the pathology. Here, we present the first evidence from human samples indicating an overabundance of opportunistic pathogens in the gut microbiome of persons with PD. The three genera that rose to significance (Porphyromonas, Prevotella, or Corynebacterium_1) represented a larger polymicrobial cluster of opportunistic pathogens that co-occur in controls as well as in patients (although at much lower abundances in healthy gut).
Per literature, these opportunist pathogens are often harmless, but can grow and cause infections if the immune system is compromised or if they penetrate sterile sites through, for example, compromised membanes. [44] [45] [46] The exciting question is whether these are Braak's pathogens capable of triggering PD, or they are irrelevant to PD but are able to penetrate the gut and grow because the gut lining is compromised in PD. We re-emphasize that no claims can be made on function based solely on association. The knowledge on the function of microorganisms in the gut is currently limited. While there may be a large body of literature, each organism has been studied with a narrow lens. Organisms that are known to be opportunistic pathogens are being looked for in clinical specimen, whether they have other critical functions is not known. The identity of these microorganisms will enable experimental studies to determine if and how they play a role in PD.
Anti-inflammatory SCFA producing bacteria Our second main finding was a polymicrobial cluster of ten genera whose relative abundances were reduced in PD. All ten genera belong to the Lachnospiraceae and Ruminococcaceae families, well-known for producing SCFA. Several studies had found reduced levels of different SCFA producing bacteria in PD patients. 12, 14, 16, 18, 19, 21, 26, 27 Our finding is therefore confirmatory, and expands on the list of PD-associated genera in these two taxonomic families. We and others noted that the decreasing levels of Lachnospiraceae correlate with increasing daily dose of levodopa, disease duration, 12 disease severity and motor impairment, 26 which suggest SCFA producing microorganisms diminish as a consequence of medication and/or advancing disease. SCFA promote gastrointestinal motility, maintain integrity of the gut lining, and control inflammation in the gut and the brain, 47, 48, [64] [65] [66] each of which are compromised in PD. It is important to note, however, that reduced levels of SCFA in the gut has been documented in many inflammatory disorders, [67] [68] [69] [70] [71] and is not specific to PD.
Probiotics
We also found elevated levels of Bifidobacterium and Lactobacillus in PD, which have been noted in some of the prior PD studies, albeit not consistently. 14, 16, 18, 21, [25] [26] [27] Both are ubiquitous inhabitants of human gut and metabolize carbohydrates derived from plants and dairy. 49, 50 We found a significant correlation between increasing levodopa dose and increasing Bifidobacterium and Lactobacillus levels. Lactobacillus produce a bacterial enzyme that metabolizes levodopa into dopamine before it can reach the brain, reducing efficacy of the drug and requiring higher doses, which in feedback causes further growth of the bacteria. 72, 73 Ironically, Bifidobacterium and Lactobacillus are sold in stores as probiotics, and a clinical trial has reported fermented milk which contained Bifidobacterium, Lactobacillus, and fiber, among other active ingredients, improved constipation in PD. 74 While generally believed to be safe, and possibly beneficial for the healthy population, they can act as opportunistic pathogens and cause infection and excessive immune stimulation in immune compromised individuals. 52, 53 It is important to understand why Bifidobacterium and Lactobacillus are elevated in PD and if they are beneficial (a compensatory mechanism to overcome the dysbiosis) or detrimental (feedback of levodopa).
Conclusion
We uncovered robust and reproducible signals, which reaffirm (SCFA, probiotics) and generate new leads (opportunistic pathogens) for experimentation into cause and effect, disease progression, and therapeutic targets. This study was limited by its singular and precise focus and intentionally conservative analytic execution. There is more to be learned with larger sample sizes with greater power, longitudinal studies to track change from prodromal to advanced disease, and by next generation metagenome sequencing to broaden the scope from bacteria and archaea to include viruses and fungi, and improve the resolution to strain and gene level.
14

Methods
Subjects and Data Collection
Subjects ( Supplementary Table 1 ) The study was approved by institutional review boards for ethical conduct of human subject research at all participating institutions. All subjects provided informed consent for their participation. Subjects were enrolled by NGRC investigators, using standardized methods, at four NGRC affiliated movement disorder clinics in United States.
Dataset 1 was collected in Seattle, WA, Albany, NY, and Atlanta, GA in 2014 and included 212 persons with PD and 136 controls. 16 Dataset 2 was collected in Birmingham, AL during 2015-2018, and included 323 PD and 184 controls (unpublished). PD was diagnosed by a movement disorder specialist using UK Brain Bank criteria, 75 and controls were self-reported free of neurological disease. Table 1 ) Data were collected using two self-administered questionnaires: an Environmental and Family History Questionnaire (EFQ) and Gut Microbiome Questionnaire (GMQ). 4, 16, 36 EFQ covered sex, age, ancestry, and lifetime exposure data on PDrelated risk factors. GMQ covered information pertinent to microbiome analysis and was filled out immediately after stool sample collection. PD medications that subjects were taking at the time of sample collection were extracted from medical records by clinical investigators.
Metadata (Supplementary
Stool samples Subjects collected stool samples at home using DNA/RNA-free sterile swabs (BD BBL CultureSwab Sterile/Media-free Swabs, Fisher Scientific, Pittsburgh, PA). The sample was collected from excreted stool (the kit is not a rectal swab), thus minimizing contamination by skin microbiota. The stool samples were shipped immediately via standard U.S. postal service at ambient temperature and stored at −20°C upon arrival. The collection kit chosen was the most reasonable option at the time (2014). Collection kits with stabilizing solutions (e.g., OMNIgene GUT by DNA Genotek) were first introduced in 2015-2016. Immediate freezing was not feasible because we could not collect stool from over 800 participants, most of whom suffer constipation, while in clinic, nor was it acceptable to the participants to place their stool in their home freezer before shipping. We tested the effect of stool sample travel time on the results as follows. Subjects recorded the collection date and we recorded when it was placed in −20°C freezer, the difference was calculated as the stool sample travel time. We tested the stool sample travel time in cases vs. controls (Supplementary Table 1 ). We adjusted the PERMANOVA and MWAS for stool sample travel time.
DNA extraction and sequencing
DNA extraction and sequencing of datasets were done in different laboratories (the Knight Lab at University of California San Diego for dataset 1, 16 
Amplicon sequence variant (ASV) inference and ASV tables
For each sequencing run: (a) a model for sequencing error was constructed using the learnErrors function specifying that all bases in all sequences be used for constructing the model, (b) sequences were de-replicated to find unique sequences using the derepFastq function, (c) ASVs were inferred from de-replicated sequences using the dada function, (d) forward and reverse sequences were merged using the mergePairs function, and (e) sequences with <250 bp or >256 bp were removed. This resulted in 1 ASV table for dataset 1 and 6 ASV tables for dataset 2. The 6 ASV tables of dataset 2 were merged using the mergeSequenceTables function. Chimeras were detected and removed using the removeBimeraDenovo function.
Data transformation
The following procedures were used to account for variable sequence depth. Sequence counts were normalized to relative abundances (calculated by dividing the number of sequences that were assigned to a unique ASV or to a genus by the total sequence count in the sample) for PERMANOVA when using Canberra or GUniFrac distance, for MWAS when using KW, and for testing correlation with levodopa drug dose. Centered-log ratio (clr) transformation (using the transform function of the microbiome v 1.4.2 R package (http://microbiome.github.com/microbiome)) was used for PCA, and for PERMANOVA when using Aitchison distance. Log ratios (implemented internally in ANCOM and SparCC) were used when using ANCOM for MWAS, and for correlation network analysis. Earlier microbiome studies (including our first study conducted with dataset 1) 16 often used rarefaction to normalize the sequence count. Although not as efficient as the other methods due to data loss, 79 for added assurance, we rarefied the data, repeated the MWAS with ANCOM, and were able to recover all 15 significant PD-associated genera.
Taxonomic assignment MWAS and correlation network analysis were conducted at genus level. To define genera, first each unique ASV was assigned to a genus using the assignTaxonomy function, which performs DADA2's native implementation of the Ribosomal Database Project (RDP) naïve Bayesian classifier, 80 using SILVA v 132 as reference and a bootstrap confidence of 80%. Then, each genus (including the unclassified genera) was formed by agglomerating all ASVs that were assigned to that genus using the tax_glom function in phyloseq.
Post MWAS, we explored PD-associated genera at the species level. DADA2 pipeline assigns ASVs to species only if the sequences match 100%. We used the addSpecies function in DADA2 with SILVA as reference and addMultiple=TRUE, first finding 100% matches, then filtering out those matches that did not correspond to the genus given by the assignTaxonomy function. To confirm and expand on DADA2-SILVA species assignments, we BLASTed ASVs against the NCBI 16S rRNA gene sequence database (downloaded on 12/3/2019), and extracted taxonomic designations with the most significant E-value. Nucleotide BLAST search was performed using the BLAST+ executables v 2.9.0 with default parameters 81 (ftp://ftp.ncbi.nlm.nih.gov/blast/executables/blast+/ ). 
Phylogenetic trees
Data Analysis and Statistics
Principal component analysis PCA was performed on the clr transformed ASV data 35 using the ordinate function in phyloseq. PC1 and PC2 were plotted using the plot_ordination function in phyloseq (Figure 1 ).
Confounders
We interrogated 47 variables (extracted from metadata) as potential confounders (Supplementary Table 1 ). In each dataset, we first tested the distribution of each variable in cases vs controls, using Fisher's exact test (fisher.test function in R) for categorical variables, and Mann-Whitney-U (wilcox.test function in R) for quantitative variables. Variables that differed between cases and control at uncorrected P<0.05 were tagged as potential confounders, and were then included in PERMANOVA, along with case-control status, and tested for their effects on microbiome composition (Table 1 ). Since PERMANOVA was conducted using marginal effects model without rank (see below), simultaneous inclusion of case-control and other variables allowed testing the association of each variable with microbiome composition while adjusting for all other variables in the model. Thus PD effect on microbiome composition (ß diversity) was adjusted for variables that differed between cases and controls. Next, variables that were associated with microbiome composition at PERMANOVA P<0.05 were included as covariates in MWAS. Thus variables that could have led to spurious taxa-disease association because they differed between cases and controls and were also associated with microbiome, were adjusted for in MWAS.
PD medications were present only in PD cases and could not be included as covariates in PERMANOVA or MWAS. To gauge the effect of PD on ß diversity independent of each medication, we performed PERMANOVA using cases not on PD medication vs. controls ( Table   1 ). The potential confounding effect of medication on differential abundance of genera was tested post-MWAS. For each genus whose relative abundance was associated with PD, we tested the correlation between relative abundance of the genus with daily dose of Levodopa (mg/day) using Spearman correlation implemented in the cor.test function in R.
Global composition of microbiome (ß diversity)
PERMANOVA was used to identify variables that had a significant effect on ß diversity (Table 1 ). Tests were conducted using adonis2 function in vegan v 2.5.3 (https://CRAN.R-project.org/package=vegan). P-values were generated by 99,999 permutations which caps at P<1E-5 as highest significance.
Three models were tested. To gauge the effect of the distance measure on the results, all three models were tested using Aitchison, 35 GUniFrac, 37 and Canberra 38 distances. Aitchison distances were calculated by first transforming the ASV data using clr, and then calculating the Euclidean distances using the vegdist function. To calculate GUniFrac distances, unrooted ASV phylogenetic trees were rooted using the root function in the ape v 5.3 R package 86 specifying the unique ASV with the highest raw count as the root, then data were transformed to relative abundances and distances were calculated using the GUniFrac function in the R package GUniFrac v 1.1, 37 specifying alpha to be 0.5. To calculate Canberra distances, data were transformed to relative abundances and distances were calculated using the vegdist function in vegan.
MWAS
We conducted MWAS to identify the genera whose abundances differed in cases vs.
controls. We chose genus classification because it is the highest resolution attainable with high confidence from 16S sequencing.
For statistical analysis of MWAS, we used ANCOM ( Table 2, and Supplementary Tables 2-3) .
We chose ANCOM because it incorporates compositionality of the microbiome data, has low false positive rate, and allows covariate adjustment. 40 To visualize the distribution of genera that were significant in MWAS (Figure 2 ), boxplots were created using ggplot2 v 3.1.0 (https://ggplot2.tidyverse.org) with a pseudo-count of 1 added to counts before transforming to relative abundances to avoid taking the log of zero during plotting.
Correlation network analysis (Figure 3 , Supplementary Figure 1 ) For each dataset, and for cases and controls separately, pairwise correlations were calculated between all genera, microbiome-wide, using log-ratio transformed relative abundances as implemented in the SparCC 43 (https://bitbucket.org/yonatanf/sparcc). Significance of each correlation was determined by pseudo P-values based on 3,000 permutations. Correlation networks were visualized by plotting all genera, microbiome-wide, and connecting correlated genera with an edge, using the program Gephi v 0.9.2. 87 We chose a minimum correlation (r) of 0.4 to connect two genera with an edge to create the graphic. All correlations r³0.4 were significant at P<3E-4, which is the maximum significance attainable with 3,000 permutations. To better visualize networks of connected genera, we first used the force-directed algorithm, Force Atlas 2, 88 then a community detection algorithm 89 as implemented in Gephi's modularity function.
Data availability Data will be publicly available at NCBI Sequence Read Archive (SRA). correlation coefficient threshold at r≥ |0.4| to connect the genera that were correlated. All correlations noted were significant at P<3E-4 (the limit for 3,000 permutations). Here we show the result for PD cases in dataset 2 because it had larger sample size and greater sequencing depth than dataset 1. (See Supplementary Figure 1 All analyses were repeated with 3 different distance measures: Aitchison, Canberra, and GUniFrac (generalized UniFrac). % variation was the inter-individual variation explained by each variable. P value was calculated using 999,999 permutations, setting the highest achievable significance at P=1E-5.
Code availability
* Analysis included subset of samples that had complete data on all 11 variables, Dataset 1 N= 160 cases, 111 controls, Dataset 2 N= 283 cases, 167 controls. ** Low power due to N<50 not on L-dopa, and <20 not on any PD medication. For other medications, N of patients not on medication was 88 to 179 in dataset 1 and 153 to 312 in dataset 2. Table 2 . PD-associated genera. MWAS was conducted in two datasets independently, testing differential abundance of genera in PD vs. controls, using two statistical methods (ANCOM and KW). The 15 genera shown are those that achieved microbiome-wide significance for association with PD in both datasets and by both methods, with (ANCOM) and without (KW) covariate adjustment (see methods for covariates). Clusters were identified hypothesis-free using correlation network analysis (Figure 3 ). PubMed search was conducted after analyses were completed using genus and species name as search term (Supplementary Table 6 ). Function (pathogen, SCFA, probiotic) was taken strictly from PubMed, and is likely oversimplified. Microbiota have been studied under a narrow lens of what is already known about them. Opportunistic pathogens are often looked for in clinical specimen with infection, SCFA bacteria are studied intensively for their anti-inflammatory and other protective effects, probiotics are understudied but highly advertised. The full function of the microbiota are not yet fully understood. In comparing results across published studies, note that a "genus" classified by one study may not be the same as the genus by the same name in another study. Taxonomic classifications and nomenclature are not standardized across reference databases. E.g., "Prevotella", as annotated in some databases including NCBI, is further divided by SILVA (used here) into several non-monophyletic groups that SILVA calls, Prevotella_2, Prevotella_6, Prevotella_7, Prevotella_9, and Prevotella (see Discussion). MWAS=microbiome-wide association study MRA= mean relative abundance in controls FC = fold change in patients (MRA in patients/MRA in controls) ANCOM= analysis of composition of microbiomes W= ANCOM score indicating the number of times a genus achieved FDR<0.05 as compared to other genera (maximum W possible: 444 in dataset 1, 560 in dataset 2). Threshold 0.8 was used for significance. All shown genera were above significance threshold. KW= Kruskal-Wallis FDR=false discovery rate NC=uncultured, not characterized
PD-associated genera
MWAS significant
